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In the September 2018 edition of Oncotarget, Quanz et al [6] . demonstrate the activity of anetumab ravtansine in combination with standard chemotherapies in ovarian cancer models. Anetumab ravtansine is an ADC that contains a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4 via a reducible disulfide linker [7] . Both in-vitro and in-vivo studies have demonstrated selective activity of anetumab ravtansine in mesothelin expressing cells and tumors including ovarian cancer [7] . In clinical testing, a phase I trial has determined the safety and maximal tolerated dose of anetumab ravtansine and it is being investigated alone or in combination therapies in several phase I/II trials for patients with mesothelin positive cancers ( Table 1 ) [8] .
The Quanz et al. studies [6] confirmed the efficacy of monotherapy with anetumab ravtansine both in vitro and in vivo. Importantly, there was a correlation between the in vivo antitumor activity of anetumab ravtansine and N/A = Non-applicable www.oncotarget.com mesothelin expression. In combination studies, treatment with anetumab ravtansine resulted in improved anti-tumor efficacy in ovarian cancer models in combination with pegylated liposomal doxorubicin which is approved in the second line for recurrent and platinum resistant ovarian cancers, than with either drug alone. Anetumab ravtansine also showed additive activity with carboplatin -another standard chemotherapeutic agent in first line treatment of ovarian cancer. Furthermore, anetumab ravtansine and the anti-angiogenic agent bevacizumab were determined to be more beneficial in combination than as monotherapy. These pre-clinical data support ongoing and future combination trials of anetumab ravtansine in patients with ovarian cancer such as the ongoing studies with pegylated liposomal doxorubicin and bevacizumab. It will be important for the clinical trials to be adequately powered for efficacy analysis as well as address several important questions such as correlation of anti-tumor activity with mesothelin expression, platinum resistance status, and determining biomarkers of response such as serum mesothelin. Although it has been almost 20 years since the first patient, a patient with ovarian cancer, was treated with a mesothelin targeted agent, these therapies are now starting to show promise in patients and, hopefully, this efficacy will be validated in randomized phase III trials [9] .
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